Press release
HIV Rapid Test Kits Market Expected to Reach US$ 4.56 Billion by 2033, Growing at a CAGR of 9.5%, North America Leads with 32% Share | Key Players Abbott Laboratories, F. Hoffmann-La Roche Ltd., Biolytical Laboratories
HIV Rapid Test Kits
HIV rapid test kits are point-of-care diagnostic tools that provide quick results, often within 20 minutes, using blood or oral fluid samples. These kits are essential for early detection, timely treatment initiation, and reducing HIV transmission rates, particularly in resource-limited and remote areas where laboratory infrastructure is limited. Technological advancements in assay sensitivity and specificity, along with the development of user-friendly and low-cost testing solutions, are further enhancing adoption. Increasing integration of rapid test kits in routine screening programs, expanded funding for HIV prevention, and enhanced distribution through pharmacies and community health centers are strengthening the long-term growth outlook of the global HIV rapid test kits market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hiv-rapid-test-kits-market?sai-v
The HIV Rapid Test Kits Market refers to the global industry focused on the development and distribution of quick, point-of-care diagnostic kits used to detect HIV antibodies or antigens within minutes.
Key Developments
✅ January 2026: In Africa, community health programs expanded distribution of HIV rapid test kits to strengthen early diagnosis efforts and linkage to care in rural regions.
✅ December 2025: In Asia-Pacific, national public health initiatives increased adoption of self-testing HIV rapid kits to improve awareness and reduce undiagnosed cases.
✅ November 2025: In North America, clinics integrated digital result reporting features with rapid test kit workflows to support surveillance and patient follow-up.
✅ October 2025: In Latin America, outreach programs deployed HIV rapid test kits in mobile health units to enhance access among key populations.
✅ September 2025: In Europe, healthcare providers expanded targeted screening with rapid test kits in community-based settings to support prevention strategies.
✅ August 2025: In the Middle East, pilot HIV rapid testing campaigns increased availability in stigma-free clinical environments to encourage uptake.
Mergers & Acquisitions
✅ January 2026: In Asia-Pacific, a regional diagnostics manufacturer acquired a rapid test kit developer to enhance its infectious disease testing portfolio.
✅ December 2025: In North America, a leading medical diagnostics company acquired a point-of-care rapid testing technology firm to strengthen its HIV and infectious disease testing offerings.
✅ November 2025: In Europe, a healthcare technology group acquired distribution rights for a global HIV rapid test kit brand to expand market reach.
Key Players
Abbott Laboratories | F. Hoffmann-La Roche Ltd. | Biolytical Laboratories | Meril Life Sciences Pvt. Ltd. | Trivitron Healthcare | Sedia Biosciences Corporation | JOYSBIO (Tianjin) Biotechnology Co., Ltd. | Xiamen Boson Biotech Co., Ltd. | Viatris Inc. | Alpine Biomedicals Pvt. Ltd.
Key Highlights
Abbott Laboratories holds 24.3% share, driven by strong global adoption of rapid diagnostic tests, wide distribution networks, and trusted HIV screening solutions used in both clinical and community settings.
F. Hoffmann-La Roche Ltd. holds 19.1% share, supported by high diagnostic accuracy standards, strong brand credibility, and integration of rapid HIV testing within broader infectious disease portfolios.
Biolytical Laboratories holds 15.6% share, benefiting from the strong global penetration of its INSTI HIV rapid test kits, ultra-fast result delivery, and widespread use in public health programs.
Meril Life Sciences Pvt. Ltd. holds 10.8% share, driven by cost-effective rapid test kits, expanding presence in emerging markets, and increasing adoption in government-led screening initiatives.
Trivitron Healthcare holds 9.4% share, supported by diversified diagnostics offerings, strong distribution across Asia, Africa, and the Middle East, and focus on affordable healthcare solutions.
Sedia Biosciences Corporation holds 6.7% share, benefiting from WHO-prequalified rapid HIV tests and strong demand from international aid agencies and NGOs.
JOYSBIO (Tianjin) Biotechnology Co., Ltd. holds 5.2% share, driven by scalable manufacturing, competitive pricing, and growing exports to developing regions.
Xiamen Boson Biotech Co., Ltd. holds 4.3% share, supported by a broad rapid diagnostics portfolio and increasing regulatory approvals across global markets.
Viatris Inc. holds 2.6% share, leveraging its global healthcare footprint and involvement in HIV-related diagnostics and treatment ecosystems.
Alpine Biomedicals Pvt. Ltd. holds 1.9% share, focused on regional rapid test manufacturing and supply for institutional and public health customers.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hiv-rapid-test-kits-market?sai-v
Market Drivers
- Rising global HIV prevalence and need for early diagnosis to improve treatment outcomes.
- Growing demand for point-of-care and self-testing solutions enabling rapid and accessible HIV screening.
- Increasing government and NGO initiatives promoting widespread HIV testing and awareness programs.
- Expansion of healthcare access in low- and middle-income regions supporting rapid test adoption.
- Advancements in rapid diagnostic technologies improving test accuracy, sensitivity, and ease of use.
Industry Developments
- Continuous innovation in lateral flow assays and rapid diagnostic test formats.
- Expansion of HIV self-test kits and home-based testing solutions.
- Strategic collaborations between diagnostic manufacturers, public health organizations, and NGOs.
- Scaling up manufacturing and distribution to support mass screening programs.
- Growing focus on regulatory approvals and quality assurance for rapid HIV diagnostic kits.
Regional Insights
North America - 32% share: "Driven by strong public health screening programs, high awareness levels, and widespread adoption of rapid diagnostic testing."
Europe - 26% share: "Supported by government-backed HIV prevention initiatives, strong healthcare systems, and increasing use of point-of-care diagnostics."
Asia Pacific - 22% share: "Fueled by large at-risk populations, expanding testing programs, and growing availability of rapid HIV test kits."
Latin America - 10% share: "Driven by increasing public health initiatives, NGO-supported testing programs, and improving access to diagnostics."
Middle East & Africa - 10% share: "Supported by high HIV burden in several countries, international aid programs, and growing adoption of rapid testing solutions."
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/hiv-rapid-test-kits-market?sai-v
Key Segments
By Technology
Lateral flow immunoassay holds the dominant share, driven by its rapid results, ease of use, and wide adoption in point-of-care and home-based testing. Immunofiltration technology accounts for a notable portion, supported by its high sensitivity and suitability for confirmatory and laboratory-supported HIV testing.
By Specimen
Blood-based testing represents the largest segment, owing to its high accuracy and long-standing clinical acceptance. Urine specimens account for a meaningful share, driven by their non-invasive nature and growing use in screening programs. Oral fluid testing is gaining traction due to ease of collection, patient comfort, and increasing availability of self-testing kits.
By Disease Type
HIV Type 1 dominates the market, reflecting its higher global prevalence and widespread screening initiatives. HIV Type 2 represents a smaller but important segment, primarily driven by testing demand in specific geographic regions and targeted diagnostic programs.
By Distribution Channel
Hospital pharmacies lead the distribution landscape, supported by high patient inflow and integration with diagnostic services. Retail pharmacies hold a substantial share, driven by increasing accessibility of rapid and self-test kits. Online pharmacies are witnessing steady growth, supported by rising e-commerce adoption, privacy concerns, and convenience in purchasing diagnostic products.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HIV Rapid Test Kits Market Expected to Reach US$ 4.56 Billion by 2033, Growing at a CAGR of 9.5%, North America Leads with 32% Share | Key Players Abbott Laboratories, F. Hoffmann-La Roche Ltd., Biolytical Laboratories here
News-ID: 4340075 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Cloud Kitchen Market Set for Strong Growth to USD 122.5 Billion by 2031, Led by …
The Global Cloud Kitchen Market size reached USD 56.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 122.5 billion by 2031. The market is expected to exhibit a CAGR of 10.1% during the forecast period 2024-2031.
Market growth is driven by surging demand for food delivery services, rapid urbanization, and changing consumer lifestyles favoring convenience. Advancements in digital platforms and apps, expanding partnerships between…
U.S. Vitamins & Minerals Supplements Market Hits USD 35.1 billion by 2035, as Pr …
The Global Vitamins and Minerals Supplements Market was estimated at 135.3 USD Billion in 2024. The Vitamins Minerals Supplements industry is projected to grow from 142.38 USD Billion in 2025 to 237.1 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.23% during the forecast period 2025 - 2035
DataM Intelligence unveils its latest report on the " Vitamins and Minerals Supplements Size 2025," offering an in-depth analysis…
United States Grow Lights Industry Report 2025: Indoor Agriculture Expansion & M …
Grow Lights market to grow at a CAGR of 13.7% during the forecast period 2024-2031.
DataM Intelligence unveils its latest report on the "Grow Lights Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with…
RNA-Based Therapies Market Expected to Reach US$ 213.54 Billion by 2033, Growing …
The global RNA-Based Therapies Market was valued at US$ 90.56 billion in 2024 and is expected to reach US$ 213.54 billion by 2033, growing at a CAGR of 10.0% during the forecast period 2025-2033. Market growth is being driven by rapid advancements in RNA delivery technologies, increasing adoption of personalized medicine, and the rising prevalence of rare genetic disorders, cancer, and infectious diseases. The commercial success of mRNA vaccines has…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
